NHD Global
Growth Hormone & IGF · Source-reviewed dossier
Source-Reviewed Research Dossier
IGF-1 LR3 is an 83-amino-acid IGF-1 analogue with an Arg3 substitution and an N-terminal extension designed to reduce binding-protein affinity. Direct literature includes recombinant-expression work and animal metabolism studies, not controlled human efficacy trials.
Shared values below are consolidated from the current catalog record. They are not independent verification or lot results; the current product specification and lot COA control.
Product identity
Literature reference parameters
Identity safeguard Reference identifiers above describe the literature compound record. The supplied form, formula, molecular weight, purity and storage conditions must be verified against the product-specific specification and lot COA.
A target-to-pathway view grounded in the linked research records.
Reported research findings
Reported outcomes are paired with their experimental model and evidence boundary.
A 2023 paper reported recombinant expression of IGF-1 and LR3 IGF-1 fusion constructs in Pichia pastoris.
Expression-system results do not verify this catalog manufacturing process.
Read the primary studyA 1999 study examined long(R3)-IGF-1 effects on protein metabolism in cattle.
Species, exposure and agricultural research context preclude human generalization.
Read the primary studyCatalog options
Pack-level catalog data; lot-level controls remain document-specific.
Single-component peptide · 0.1 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Single-component peptide · 1 mg/vial nominal · 10-vial pack · supplied form and release limits controlled by lot specification.
Request by lot: CoA, HPLC purity and MS identity
Document availability is stated honestly and can vary by catalog variant or lot.
Analytical interpretation
Use the source-reviewed guide to separate chromatographic area purity, quantitative assay, LC-MS identity, composition and stability evidence before comparing variants or requesting a lot record.
Open the Quality & Documentation HubHPLC area ≠ assayA dominant peak does not establish target mass fraction.
Intact mass ≠ full sequenceIdentity strength depends on resolution and orthogonal evidence.
Counterions affect contentWater, salt form and solvents change the as-is composition.
Storage needs a data basisShipping practice is not the same as stability evidence.
Evidence map
Published studies and regulatory records, not customer testimonials or usage guidance.
Expression-system results do not verify this catalog manufacturing process.
View primary recordSpecies, exposure and agricultural research context preclude human generalization.
View primary recordThird-party publications selected for direct relevance.
Biotechnology study. 2023. PMID 37261455.
Animal study. 1999. PMID 10370861.
Concise answers for researchers comparing identity, evidence and catalog variants.
IGF-1 LR3 is an 83-amino-acid IGF-1 analogue with an Arg3 substitution and an N-terminal extension designed to reduce binding-protein affinity. Direct literature includes recombinant-expression work and animal metabolism studies, not controlled human efficacy trials.
Direct evidence is limited to laboratory production and non-human models.
No. The cited records describe their own intervention, formulation, model and controls. They do not verify the identity, purity, sterility, safety or efficacy of a catalog lot.
A lot-specific COA, product specification sheet and analytical method summary can be requested where applicable.
Store at -20 °C, protected from light and moisture. After reconstitution, aliquot and avoid repeated freeze-thaw cycles. Confirm the applicable storage statement on the product-specific specification and lot documentation.
Knowledge center
Owned educational content connected to this family.
Direct Long R3 IGF-1 literature is largely about recombinant production and animal biology. Some endpoints changed, while a 739-oocyte comparison found no difference in…
Updated September 8, 2026
Long R3 IGF-1 is an 83-amino-acid IGF-1 analogue with an Arg substitution at position 3 and a 13-residue N-terminal extension. It is not interchangeable…
Updated September 8, 2026Knowledge tools
Move from this dossier into canonical evidence maps, verified status records, analytical interpretation and laboratory calculations.
Claims were checked against the linked primary publication, regulatory label or authoritative compound record. Published findings stay attached to their study model, formulation and route. Catalog identity and lot quality remain controlled by the applicable specification and lot-specific documents.
Technical procurement
Selected: IG01 · 0.1 mg × 10 vials
Tell us what you need. Your enquiry will be routed to the appropriate contact for catalog numbers, availability and quotation details.
